In addition, higher doses of recombinant activated factor VII (0.343 ± 1.031 vs. 0.134 ± 0.615, P = 0.008) and prothrombin complex concentrate (602.367 ± 410.826 vs. 506.719 ± 359.224, P = 0.01) were administrated in the patients without pneumonia than those with pneumonia. This evidence concerns the gene F7 and susceptibility to pneumonia measurement.